Redx Pharma (LON:REDX) Stock Price Passes Below 50 Day Moving Average of $12.95

Shares of Redx Pharma Plc (LON:REDXGet Free Report) crossed below its 50 day moving average during trading on Tuesday . The stock has a 50 day moving average of GBX 12.95 ($0.17) and traded as low as GBX 11.42 ($0.15). Redx Pharma shares last traded at GBX 15 ($0.19), with a volume of 1,420,135 shares changing hands.

Redx Pharma Stock Performance

The firm has a fifty day moving average of GBX 12.95 and a 200-day moving average of GBX 18.38. The company has a quick ratio of 1.93, a current ratio of 1.11 and a debt-to-equity ratio of 527.00. The stock has a market capitalization of £58.35 million, a price-to-earnings ratio of -150.00 and a beta of -0.53.

Insider Buying and Selling at Redx Pharma

In other news, insider Lisa Anson bought 399,000 shares of the business’s stock in a transaction that occurred on Thursday, April 11th. The stock was purchased at an average price of GBX 8 ($0.10) per share, with a total value of £31,920 ($40,896.86). 18.35% of the stock is owned by insiders.

About Redx Pharma

(Get Free Report)

Redx Pharma Plc engages in drug discovery, pre-clinical development, and licensing activities in the United Kingdom. It discovers and develops small molecule drugs for treating fibrotic disease, cancer, and the emerging area of cancer-associated fibrosis in the areas of unmet medical needs. The company also develops zelasudil (RXC007), a selective rho associated coiled-coil containing protein kinase 2 (ROCK2) inhibitor, which is in Phase 2 clinical trial for the treatment of multiple interstitial lung diseases and cancer-associated fibrosis; RXC008, a potential first-in-class GI-targeted ROCK inhibitor that is in preclinical studies for the treatment of fibrostenotic Crohn's disease; and zamaporvint (RXC004), a porcupine inhibitor that is in Phase 2 clinical trial for targeted therapy of Wnt-ligand dependent cancers.

Featured Articles

Receive News & Ratings for Redx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.